RCMNY
PNT

Rubric Capital Management (New York)’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Rubric Capital Management (New York)’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-190,000
Closed -$1.72M – 72
2023
Q2 		$1.72M Sell
190,000
-2,455,336
-93% -$21.7M 0.07% 59
2023
Q1 		$19.2M Buy
2,645,336
+818,032
+45% +$6.07M 0.5% 44
2022
Q4 		$13.3M Buy
+1,827,304
New +$13.6M 0.58% 48

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rubric Capital Management (New York)'s PNT Position: Q3 2023 in Review

Rubric Capital Management (New York) sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 190,000 shares — an estimated $1.72M sold.

Rubric Capital Management (New York) first reported a position in PNT in Q4 2022 and held it in 3 quarters. The position peaked at $19.2M in Q1 2023. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Rubric Capital Management (New York) reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 190,000 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $1.72M.
  • Rubric Capital Management (New York) first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s POINT Biopharma Global Inc. Common Stock position peaked at $19.2M in Q1 2023.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.